Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Bone metabolism drugs (bisphosphonates, RANKL inhibitors). These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Question 1: A 69-year-old man with type 2 diabetes mellitus comes to the physician for a follow-up examination. His only medication is metformin. He has tried to lose weight for several years without success. He is 168 cm (5 ft 6 in) tall and weighs 110 kg (243 lb); BMI is 39 kg/m2. His hemoglobin A1c is 8.5%. Which of the following is the most appropriate antidiabetic drug to address both this patient's glucose control and weight?
- A. Nateglinide
- B. Rosiglitazone
- C. Liraglutide (Correct Answer)
- D. Miglitol
- E. Glipizide
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) Explanation: ***Liraglutide***
- **Liraglutide** is a **glucagon-like peptide-1 (GLP-1) receptor agonist** that improves glycemic control by increasing glucose-dependent insulin secretion, decreasing glucagon secretion, and slowing gastric emptying.
- A significant side effect of GLP-1 agonists is **weight loss**, making it an ideal choice for this patient who is obese (BMI 39 kg/m2) and struggling with weight management while having suboptimal glycemic control (HbA1c 8.5%).
*Nateglinide*
- **Nateglinide** is a **meglitinide**, which stimulates insulin release from pancreatic beta cells, similar to sulfonylureas, but with a more rapid and short-lived effect.
- While it helps in glucose control, it is often associated with **weight gain** and does not address the patient's desire for weight loss.
*Rosiglitazone*
- **Rosiglitazone** is a **thiazolidinedione (TZD)** that improves insulin sensitivity by acting on PPAR-gamma receptors.
- TZDs are commonly associated with **weight gain** and fluid retention, which would be detrimental to this patient's weight management goals.
*Miglitol*
- **Miglitol** is an **alpha-glucosidase inhibitor** that delays the absorption of carbohydrates from the gut, reducing postprandial glucose excursions.
- While it can help with glucose control and is weight-neutral or may cause modest weight loss, its efficacy in reducing HbA1c is generally lower compared to other agents, and it commonly causes **gastrointestinal side effects** like flatulence and diarrhea.
*Glipizide*
- **Glipizide** is a **sulfonylurea** that stimulates insulin secretion from pancreatic beta cells independently of glucose concentration.
- It is associated with a risk of **hypoglycemia** and often leads to **weight gain**, which is not suitable for a patient who needs to lose weight.
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Question 2: A scientist is studying the anatomy and function of bone growth. He is able to create a cell line of osteocytes with a mutation that prevents the osteocytes from exchanging nutrients and waste products within neighboring lamellae. This mutation most likely affected which of the following cell structures?
- A. Dynein
- B. Gap junctions (Correct Answer)
- C. Endoplasmic reticulum
- D. Plasma membrane
- E. Kinesin
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) Explanation: ***Gap junctions***
- **Gap junctions** are specialized intercellular connections that permit direct communication and exchange of small molecules and ions between adjacent cells.
- In osteocytes, **gap junctions** located in the **canaliculi** are crucial for the exchange of nutrients, waste, and signaling molecules within and between lamellae, allowing for synchronous activity and maintaining bone health.
- These connexin-based channels physically connect the cytoplasm of neighboring osteocytes embedded in bone matrix.
*Dynein*
- **Dynein** is a motor protein involved in intracellular transport towards the minus end of **microtubules**, playing a role in moving organelles and vesicles.
- It is not directly responsible for the intercellular exchange of nutrients and waste products between cells.
*Endoplasmic reticulum*
- The **endoplasmic reticulum** is an organelle involved in protein synthesis and lipid metabolism, playing a critical role in cellular function.
- It does not directly mediate the exchange of nutrients and waste products between adjacent cells.
*Plasma membrane*
- While **gap junctions** are embedded within the **plasma membrane**, the membrane itself does not facilitate direct cytoplasmic continuity between cells.
- The question specifically refers to structures that enable direct cell-to-cell exchange; the mutation affects the gap junction channels themselves (connexins), not the general plasma membrane structure.
- Without functional gap junctions, the plasma membrane alone cannot support the intercellular communication required for osteocyte networks.
*Kinesin*
- **Kinesin** is a motor protein that moves cargo along **microtubules** towards the plus end, involved in fundamental cellular processes like cell division and organelle transport.
- It is not involved in direct intercellular communication for nutrient and waste exchange but rather internal cellular trafficking.
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Question 3: A 67-year-old woman presents to her physician for a regular checkup. She is a community-dwelling, retired teacher without any smoking history. She has arterial hypertension and takes hydrochlorothiazide 12.5 mg and valsartan 80 mg daily. She was recently discharged from the hospital after admission for an ulnar fracture she received after a fall from the second step of a ladder in her garden. A year ago, she had a clavicular fracture from tripping over some large rocks in her yard. She does not report lightheadedness or fainting. Her medical history is also significant for an appendectomy 11 years ago. She is in menopause. She mostly consumes vegetables and dairy products. Her height is 163 cm (5 ft 4 in) and weight is 55 kg (123 lb). Her blood pressure is 130/80 mm Hg without orthostatic changes, heart rate is 73/min and regular, respiratory rate is 14/min, and temperature is 36.6°C (97.9°F). Her lungs are clear to auscultation. Cardiac auscultation reveals S2 accentuation over the aorta. The abdomen is mildly distended on palpation; there are no identifiable masses. The neurological examination is unremarkable. Considering the history and presentation, which of the following medications most likely will be prescribed to this patient after additional investigations?
- A. Estrogen plus progestin
- B. Denosumab
- C. Cholecalciferol (Correct Answer)
- D. Atorvastatin
- E. Tocopherol
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) Explanation: ***Cholecalciferol***
- The patient presents with multiple risk factors for **osteoporosis** and potential **vitamin D deficiency**, including postmenopausal status, multiple fragility fractures (ulnar and clavicular), and a diet rich in vegetables but potentially low in vitamin D-fortified products or sun exposure.
- **Cholecalciferol (Vitamin D3)** is essential for calcium absorption and bone health, and its supplementation is crucial for preventing and managing osteoporosis, particularly when low levels are suspected.
*Estrogen plus progestin*
- **Hormone replacement therapy (HRT)** with estrogen plus progestin can prevent osteoporosis, but it is typically not a first-line treatment due to increased risks of breast cancer, cardiovascular events, and stroke, especially in a 67-year-old woman.
- Given her age and that she is well past menopause, the risks often outweigh the benefits for bone health alone, and safer alternatives are available for osteoporosis treatment.
*Denosumab*
- **Denosumab** is a potent antiresorptive agent used for osteoporosis, particularly in patients with a high fracture risk or those who cannot tolerate oral bisphosphonates.
- While she has risk factors for osteoporosis, denosumab is usually initiated after a definitive diagnosis of osteoporosis (e.g., via **DEXA scan**) and often after lifestyle modifications and basic supplementation like vitamin D. It's a treatment, not a "most likely prescribed after additional investigation" first step.
*Atorvastatin*
- **Atorvastatin** is a statin used to lower cholesterol and prevent cardiovascular disease.
- While the patient has hypertension, there's no indication in the provided information (e.g., lipid profile, history of cardiovascular events) that she requires atorvastatin at this time.
*Tocopherol*
- **Tocopherol (Vitamin E)** is an antioxidant that plays a role in various bodily functions but is not directly involved in bone metabolism or the prevention/treatment of osteoporosis.
- There is no clinical indication in the patient's history suggesting a need for vitamin E supplementation for her current presentation.
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Question 4: A 62-year-old man comes to the physician for hematemesis and progressive heartburn over the past 5 days. Ten days ago, he was started on a medication to treat a condition that causes hearing difficulties and pain of the lower legs. He has no other history of serious illness. He has smoked 1 pack of cigarettes daily for the past 20 years. Physical examination shows bowing of the tibias. Upper endoscopy shows inflammation of the mucosa and a 1-cm punched-out ulcer in the distal esophagus. Which of the following drugs is the most likely cause of the patient's current condition?
- A. Denosumab
- B. Risedronate (Correct Answer)
- C. Calcium citrate
- D. Acetaminophen
- E. Prednisolone
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) Explanation: ***Risedronate***
- The patient's history of hearing difficulties, lower leg pain, and bowing of the tibias suggests **Paget's disease of bone**. Bisphosphonates like **risedronate** are a common treatment for Paget's disease.
- Bisphosphonates are well-known to cause **esophagitis, esophageal ulcers**, and inflammation of the mucosa, leading to symptoms like **heartburn** and **hematemesis**.
*Denosumab*
- **Denosumab** is also used to treat Paget's disease but is a **monoclonal antibody** that inhibits osteoclast formation and function.
- It works differently from bisphosphonates and is not typically associated with **esophageal erosion** or **ulcers**.
*Calcium citrate*
- **Calcium citrate** is a calcium supplement often used to prevent or treat **osteoporosis**, not a primary treatment for Paget's disease.
- It does not cause **esophageal ulcers** or inflammation.
*Acetaminophen*
- **Acetaminophen** is an analgesic and antipyretic, not used for Paget's disease, and its primary side effect is **hepatotoxicity** at high doses.
- It **does not cause esophageal damage** or ulcers.
*Prednisolone*
- **Prednisolone** is a corticosteroid that can cause **gastric ulcers** but is not a first-line treatment for Paget's disease.
- While it can cause gastrointestinal side effects, it is less directly implicated in **esophageal ulcers** in this context compared to bisphosphonates.
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Question 5: A 69-year-old woman comes to the clinic for an annual well exam. She reports no significant changes to her health except for an arm fracture 3 weeks ago while she was lifting some heavy bags. Her diabetes is well controlled with metformin. She reports some vaginal dryness that she manages with adequate lubrication. She denies any weight changes, fevers, chills, palpitations, nausea/vomiting, incontinence, or bowel changes. A dual-energy X-ray absorptiometry (DEXA) scan was done and demonstrated a T-score of -2.7. She was subsequently prescribed a selective estrogen receptor modulator, in addition to vitamin and weight-bearing exercises, for the management of her symptoms. What is the mechanism of action of the prescribed medication?
- A. Estrogen antagonist in cervix and agonist in bone
- B. Estrogen agonist in bone and breast
- C. Estrogen antagonist in breast and agonist in bone (Correct Answer)
- D. Partial estrogen agonist in endometrium and bone
- E. Partial estrogen agonist in bone and antagonist in cervix
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) Explanation: ***Estrogen antagonist in breast and agonist in bone***
- Selective estrogen receptor modulators (SERMs) like **raloxifene** act as **estrogen agonists in bone**, helping to prevent osteoporosis by increasing bone mineral density.
- They also act as **estrogen antagonists in breast tissue**, which can reduce the risk of breast cancer in high-risk postmenopausal women.
- This is the mechanism of the medication prescribed for this patient's osteoporosis (T-score -2.7).
*Estrogen antagonist in cervix and agonist in bone*
- While SERMs are **agonists in bone**, they do not typically have significant antagonistic effects on the cervix, which is not a primary target for their therapeutic action or side effect profile.
- The primary antagonism is observed in breast tissue, not the cervix.
*Estrogen agonist in bone and breast*
- This describes the action of **estrogen replacement therapy (ERT)**, which increases breast cancer risk, whereas SERMs are designed to avoid this by being antagonists in breast tissue.
- The goal of SERMs is to achieve the beneficial bone effects of estrogen without the undesirable estrogenic effects on breast tissue.
*Partial estrogen agonist in endometrium and bone*
- Some SERMs, particularly **tamoxifen**, can act as a **partial estrogen agonist in the endometrium**, which can increase the risk of endometrial hyperplasia or cancer.
- However, raloxifene (a common SERM for osteoporosis) is typically **neutral or minimally agonistic** on the endometrium, and the primary description here is for its breast and bone effects.
*Partial estrogen agonist in bone and antagonist in cervix*
- SERMs are indeed **agonists in bone**, but their antagonistic action is primarily in the breast, not the cervix.
- The cervix is not a key target for either agonist or antagonist effects in the context of SERM therapeutic use for osteoporosis and breast cancer risk reduction.
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Question 6: A 64-year-old woman presents to the clinic with a history of 3 fractures in the past year with the last one being last month. Her bone-density screening from last year reported a T-score of -3.1 and she was diagnosed with osteoporosis. She was advised to quit smoking and was asked to adapt to a healthy lifestyle to which she complied. She was also given calcium and vitamin D supplements. After a detailed discussion with the patient, the physician decides to start her on weekly alendronate. Which of the following statements best describes this patient’s new therapy?
- A. It should be stopped after 10 years due to the risk of esophageal cancer
- B. It is typically used as a second-line therapy for her condition after raloxifene
- C. It can cause hot flashes, flu-like symptoms, and peripheral edema
- D. It must be taken with the first meal of the day due to the significant risk of GI upset
- E. The patient must stay upright for at least 30 minutes after taking this medication (Correct Answer)
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) Explanation: ***The patient must stay upright for at least 30 minutes after taking this medication***
- This instruction is crucial for **alendronate** (a bisphosphonate) to prevent **esophageal irritation** and potential esophagitis or ulcers.
- Alendronate must be taken with a full glass of plain water on an **empty stomach** at least 30-60 minutes before the first food, beverage, or other medication of the day, and the patient must remain upright.
*It should be stopped after 10 years due to the risk of esophageal cancer*
- The main concern with long-term bisphosphonate use (usually >5 years for oral agents) is the risk of **atypical femoral fractures** and **osteonecrosis of the jaw**, not esophageal cancer.
- While esophageal irritation is a known side effect, the risk of esophageal cancer is **not the primary reason** for treatment discontinuation after 10 years.
*It is typically used as a second-line therapy for her condition after raloxifene*
- **Alendronate** (an oral bisphosphonate) is considered a **first-line therapy** for postmenopausal osteoporosis, especially in patients with a history of fractures and low T-scores.
- **Raloxifene** is a selective estrogen receptor modulator (SERM) typically used when bisphosphonates are contraindicated or not tolerated, or there is a need to also treat breast cancer risk, and it is **less potent** in reducing non-vertebral fractures.
*It can cause hot flashes, flu-like symptoms, and peripheral edema*
- These side effects (hot flashes, flu-like symptoms, peripheral edema) are **not typically associated** with alendronate.
- **Hot flashes** are more common with estrogen-modulating drugs like raloxifene, while **flu-like symptoms** can occur with IV bisphosphonates (like zoledronic acid) or certain anabolic agents.
*It must be taken with the first meal of the day due to the significant risk of GI upset*
- This statement is incorrect; alendronate must be taken on an **empty stomach** (at least 30-60 minutes before the first food or drink) to ensure adequate absorption.
- Taking it with food or other beverages significantly **reduces its absorption**, making it less effective, and the risk of GI upset (specifically esophageal irritation) is why remaining upright and taking with water are stressed.
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Question 7: A 67-year-old Caucasian female presents to her primary care physician after a screening DEXA scan reveals a T-score of -3.0. Laboratory work-up reveals normal serum calcium, phosphate, vitamin D, and PTH levels. She smokes 1-2 cigarettes per day. Which of the following measures would have reduced this patient's risk of developing osteoporosis?
- A. Weight loss
- B. Reduced physical activity to decrease the chance of a fall
- C. Initiating a swimming exercise program three days per week
- D. Calcium and vitamin D supplementation
- E. Smoking cessation (Correct Answer)
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) Explanation: ***Smoking cessation***
- **Smoking** is a well-established, modifiable risk factor for osteoporosis that directly impairs bone metabolism
- Cigarette smoking **decreases osteoblast activity**, increases **bone resorption**, and reduces intestinal calcium absorption
- This patient is **actively smoking 1-2 cigarettes per day**, making cessation the most relevant preventive measure for her specific situation
- **Smoking cessation** would have directly addressed a harmful exposure that contributed to her bone loss
*Calcium and vitamin D supplementation*
- While important for bone health, this patient's laboratory work-up shows **normal serum calcium and vitamin D levels**
- Supplementation beyond adequate levels has **limited additional benefit** for osteoporosis prevention in patients with normal baseline values
- Supplementation is most beneficial in patients with documented **deficiency** or inadequate dietary intake
*Weight loss*
- **Weight loss** and being underweight are actually **risk factors for osteoporosis**
- Lower body weight reduces mechanical loading on bones, which is necessary for maintaining bone density
- Weight-bearing stress stimulates bone formation through mechanotransduction
*Initiating a swimming exercise program three days per week*
- While **swimming** is excellent for cardiovascular fitness and overall health, it is **not a weight-bearing exercise**
- Osteoporosis prevention requires **weight-bearing or resistance exercises** such as walking, jogging, dancing, or strength training
- These activities provide the mechanical stress needed to stimulate bone formation
*Reduced physical activity to decrease the chance of a fall*
- **Reducing physical activity** accelerates bone loss due to decreased mechanical loading
- While fall prevention is important in osteoporosis management, it should focus on **environmental modifications** and **balance training**, not activity reduction
- Maintaining appropriate physical activity is essential for preserving bone density
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Question 8: A 69-year-old African American man is brought to the emergency department with sudden onset lower limb paralysis and back pain. He has had generalized bone pain for 2 months. He has no history of severe illnesses. He takes ibuprofen for pain. On examination, he is pale. The vital signs include: temperature 37.1°C (98.8°F), pulse 68/min, respiratory rate 16/min, and blood pressure 155/90 mm Hg. The neurologic examination shows paraparesis. The 8th thoracic vertebra is tender to palpation. An X-ray of the thoracic vertebrae confirms a compression fracture at the same level. The laboratory studies show the following:
Laboratory test
Hemoglobin 9 g/dL
Mean corpuscular volume 95 μm3
Leukocyte count 5,000/mm3
Platelet count 240,000/mm3
ESR 85 mm/hour
Serum
Na+ 135 mEq/L
K+ 4.2 mEq/L
Cl− 113 mEq/L
HCO3− 20 mEq/L
Ca+ 11.5 mg/dL
Albumin 4 g/dL
Urea nitrogen 18 mg/dL
Creatinine 1.2 mg/dL
Serum electrophoresis shows a monoclonal protein level of 38 g/L. To reduce the likelihood of fracture recurrence, it is most appropriate to administer which of the following?
- A. Calcitonin
- B. Calcitriol
- C. Pamidronate (Correct Answer)
- D. Fluoride
- E. Testosterone
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) Explanation: ***Pamidronate***
- The patient's presentation with **bone pain**, **hypercalcemia**, **anemia**, **elevated ESR**, **renal insufficiency**, and a **monoclonal protein** in serum electrophoresis is highly suggestive of **multiple myeloma**.
- **Bisphosphonates** like pamidronate are crucial in managing multiple myeloma by inhibiting osteoclast activity, reducing bone resorption, and thereby decreasing the risk of **pathological fractures** and managing **hypercalcemia**.
*Calcitonin*
- **Calcitonin** primarily works to lower serum calcium levels quickly but has a less sustained effect on bone remodeling compared to bisphosphonates.
- While it can be used for acute hypercalcemia, its role in preventing long-term fracture recurrence in multiple myeloma is limited.
*Calcitriol*
- **Calcitriol**, the active form of **vitamin D**, promotes calcium absorption from the gut and bone mineralization.
- Administering calcitriol in a patient with pre-existing hypercalcemia due to multiple myeloma would worsen the condition.
*Fluoride*
- **Fluoride** can increase bone density by affecting hydroxyapatite crystal formation.
- However, high doses of fluoride can lead to **fluorosis** and paradoxically increase bone fragility, making it unsuitable for preventing fractures in multiple myeloma.
*Testosterone*
- **Testosterone** is an anabolic steroid that can improve bone density in individuals with **hypogonadism**.
- It is not indicated for preventing fractures in the context of multiple myeloma, where bone destruction is driven by osteoclast activation due to plasma cell proliferation.
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Question 9: A 58-year-old man comes to the physician because of a 6-month history of headaches and back pain. Examination shows mild sensorineural hearing loss. Serum concentration of alkaline phosphatase is increased. An x-ray of the skull is shown. The most appropriate pharmacotherapy for this patient is a drug that has which of the following mechanisms of action?
- A. Inhibition of proteasomes
- B. Inhibition of tubulin polymerization
- C. Apoptosis of osteoclasts (Correct Answer)
- D. Formation of DNA strand breaks
- E. Inhibition of nuclear factor-κB
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) Explanation: ***Apoptosis of osteoclasts***
- The patient's symptoms (headaches, back pain, sensorineural hearing loss, elevated alkaline phosphatase) and the skull X-ray showing diffuse sclerosis (\"cotton wool\" appearance) are classic for **Paget's disease of bone**.
- **Bisphosphonates** (which induce osteoclast apoptosis) are the first-line treatment for Paget's disease by reducing abnormal bone turnover.
*Inhibition of proteasomes*
- This mechanism of action is characteristic of drugs like **bortezomib**, which are primarily used in the treatment of **multiple myeloma**.
- Multiple myeloma causes osteolytic lesions and hypercalcemia, but the X-ray findings and overall clinical picture are not consistent with this diagnosis.
*Inhibition of tubulin polymerization*
- Drugs that inhibit tubulin polymerization, such as **colchicine** (for gout) or **vincristine/vinblastine** (for various cancers), prevent cell division and migration.
- This mechanism is not relevant to the pathophysiology or treatment of Paget's disease.
*Formation of DNA strand breaks*
- This is the mechanism of action for certain **chemotherapeutic agents** (e.g., alkylating agents, platinum compounds) that damage DNA to kill rapidly dividing cancer cells.
- Paget's disease is a disorder of bone remodeling, not a primary malignancy requiring such aggressive therapy.
*Inhibition of nuclear factor-κB*
- **NF-κB** is a protein complex that controls transcription of DNA and is involved in immune responses and inflammation.
- While NF-κB inhibitors are being investigated for various inflammatory conditions and cancers, they are not the primary pharmacotherapy for Paget's disease of bone.
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG Question 10: A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3–4 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for which of the following adverse effects?
- A. Hepatic steatosis
- B. Abnormal dreams
- C. Pancytopenia (Correct Answer)
- D. Orthostatic dysregulation
- E. Hyperglycemia
Bone metabolism drugs (bisphosphonates, RANKL inhibitors) Explanation: ***Pancytopenia***
- **Valganciclovir** is a known cause of **bone marrow suppression**, leading to **pancytopenia** (low red blood cells, white blood cells, and platelets).
- The patient is also on **zidovudine**, an antiretroviral that can cause **myelosuppression**, thus the combined use significantly increases the risk of pancytopenia.
*Hepatic steatosis*
- **Hepatic steatosis** (fatty liver) is a rare but known adverse effect of some nucleoside reverse transcriptase inhibitors (NRTIs), particularly older ones.
- While lamivudine is an NRTI, **valganciclovir** is not primarily associated with hepatic steatosis, and the combination does not specifically heighten this risk more than other options.
*Abnormal dreams*
- **Abnormal dreams** are a common side effect associated with certain antiretroviral drugs, particularly the non-nucleoside reverse transcriptase inhibitor **efavirenz**.
- This patient is on dolutegravir (an integrase inhibitor), zidovudine, and lamivudine, none of which are primarily known for causing abnormal dreams as a prominent side effect, and valganciclovir does not contribute to this.
*Orthostatic dysregulation*
- **Orthostatic dysregulation** (orthostatic hypotension) can be a side effect of various medications, but it is not a prominent adverse effect of either **valganciclovir** or the patient's current antiretroviral regimen.
- While dehydration from diarrhea can cause it, the medication itself does not directly increase this risk in particular.
*Hyperglycemia*
- **Hyperglycemia** can be a side effect of certain antiretroviral drugs, particularly some **protease inhibitors** and older NRTIs.
- However, the patient's current regimen (zidovudine, lamivudine, dolutegravir) and **valganciclovir** are not strongly associated with hyperglycemia as a primary adverse effect compared to other options.
More Bone metabolism drugs (bisphosphonates, RANKL inhibitors) US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
